DoubleStim uses a combination of simultaneous non-invasive spinal and peripheral stimulations. Image source: pmneuro.com
PathMaker Neurosystems, a clinical-stage neurotechnology company developing non-invasive neurotherapy systems for the treatment of patients with neuromotor disorders, announced that the U.S. Patent and Trademark Office has granted a fundamental patent (U.S. Patent 9,283,391) covering its proprietary DoubleStim technology that forms the basis of our MyoRegulator system, a first-in-class non-invasive device now in human clinical trials for the treatment of muscle spasticity.
DoubleStim uses a combination of simultaneous non-invasive spinal and peripheral stimulations. In our first implementation, the stimulation is directed to suppression of hyperexcitable spinal cord circuits that are involved in spasticity. DoubleStim technology is the basis of our MyoRegulator PM-2200 system, which is currently in development for the treatment of muscle spasticity in patients with stroke, cerebral palsy, multiple sclerosis, spinal cord injury, traumatic brain injury and numerous other neurological conditions. These patients often have spasticity that severely limits motor control and impacts daily activities and quality of life.
The MyoRegulator system addresses a major unmet need for safe and effective therapies that can non-invasively and durably reverse muscle spasticity. MyoRegulator was one of the first products accepted into U.S. Food and Drug Administration’s new “Expedited Access Pathway” intended for breakthrough products, and is now in IRB-approved human clinical trials at Northwell Health/Feinstein Institute for Medical Research. MyoRegulator is an investigational device and is limited by U.S. law to investigational use only.
PathMaker Neurosystems
www.pmneuro.com
